Senaparib

Senaparib
Clinical data
Other names	IMP-4297
Legal status
Legal status	Invesigational;
Identifiers
	IUPAC name 5-fluoro-1-[[4-fluoro-3-(4-pyrimidin-2-ylpiperazine-1-carbonyl)phenyl]methyl]quinazoline-2,4-dione;
CAS Number	1401682-78-7 ;
PubChem CID	68389008 ;
DrugBank	DB17163 ;
ChemSpider	103704755 ;
UNII	MNZ4OP95CF ;
ChEMBL	ChEMBL4802152 ;
Chemical and physical data
Formula	C24H20F2N6O3
Molar mass	478.460 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1CN(CCN1C2=NC=CC=N2)C(=O)C3=C(C=CC(=C3)CN4C5=C(C(=CC=C5)F)C(=O)NC4=O)F;
	InChI InChI=1S/C24H20F2N6O3/c25-17-6-5-15(14-32-19-4-1-3-18(26)20(19)21(33)29-24(32)35)13-16(17)22(34)30-9-11-31(12-10-30)23-27-7-2-8-28-23/h1-8,13H,9-12,14H2,(H,29,33,35); Key:VBTUJTGLLREMNW-UHFFFAOYSA-N;

Last updated June 30, 2025

Senaparib is an investigational new drug that is being evaluated to treat ovarian cancer.^[1] It is a PARP inhibitor.^[2]

References

↑ "Senaparib - IMPACT Therapeutics". AdisInsight. Springer Nature Switzerland AG.
↑ Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE (June 2024). "The discovery of a potent PARP1 inhibitor Senaparib". Molecular Cancer Therapeutics. 24 (1): OF1 –OF9. doi:10.1158/1535-7163.MCT-23-0625. PMID 38920409.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Senaparib - IMPACT Therapeutics". AdisInsight. Springer Nature Switzerland AG.

[Cai_2024-2] Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE (June 2024). "The discovery of a potent PARP1 inhibitor Senaparib". Molecular Cancer Therapeutics. 24 (1): OF1 –OF9. doi:10.1158/1535-7163.MCT-23-0625. PMID 38920409.

[1]

[2]